Maropitant citrate (Cerenia™ )

Jump to... Uses Administration Pharmocokinetics Precautions Adverse Reactions Antidotes Preparations Sources

• Maropitant citrate.

• Anti-emetic.
• Neurokinin (NK1) receptor antagonist.

• (2S,3S)-2-benzhydryl- N-(5- tert-butyl-2-methoxybenzyl)quinuclidin-3-amine citrate monohydrate.

• C32H40N20C6H807H20

• 678.81

• Peach-colored oval tablets (16, 24, 60 and 160 mg of maropitant as maropitant citrate per tablet).
• Injectable solution (10 mg maropitant, 63 mg sulphobutylether-beta-cyclodextrin, 3.3 mg meta-cresol and water).

• Store at controlled room temperature (20-25°C; 68-77°F) with excursions between 15-30°C (59-86°F).
• Use vial of injectable solution within 28 days of first vial puncture.

Uses

Top

• Neurokinin (NK1) receptor antagonist that blocks the pharmacological action of substance P in the CNS.

• Prevention of emesis .
• Prevention of emesis associated with motion sickness.

Administration

Top

• Sub-cutaneous injection.
• Oral.

Acute vomiting

• Tablets : minimum dose of 2 mg/kg (0.9 mg/lb) body weight SID for up to 5 consecutive days.
• Injectable solution : 1.0 mg/kg (0.45 mg/lb) equal to 1.0 ml/10 kg (1.0 ml/22 lb) of body weight SC SID for up to 5 consecutive days.
  Tablets and injectable solution can be used interchangeably for once daily dosing for the prevention of acute vomiting.

Motion sickness

• Minimum dose of 8 mg/kg (3.6 mg/lb) body weight SID for up to 2 consecutive days.
• Dogs should be fasted 1 hour prior to administration.
• Administer tablets 2 hours prior to travel.
  Both tablets and injectable solutions recommended for use in dogs 16 weeks and older.

Pharmocokinetics

Top

• The safe use of Cerenia™ has not been evaluated in dogs used for breeding, pregnant or lactating bitches, dogs with gastrointestinal obstruction, or dogs that have ingested toxins.

• Use with caution in dogs with hepatic dysfunction.

Precautions

Top

• In puppies <11 weeks of age, histological evidence of bone marrow hypoplasia was seen at higher frequency and greater severity in puppies treated with Cerenia™ than in control puppies. In puppies 16 weeks and older, bone marrow hypoplasia was not seen.

• Use with caution with other protein bound drugs. The concomitant use of Cerenia™ with other protein bound drugs such as NSAIDs, cardiac, anticonvulsant and behavioral medications has not been evaluated.

Sources

Top

• Recent references from PubMed.
• Benchaoui H A, Siedek E M, de la Puente-Redondo V A, Tilt N, Rowan T G & Clemence R G (2007) Efficacy of maropitant for preventing vomiting associated with motion sickness in dogs. Vet Rec 161 , 444-447 PubMed.
• Benchaoui H A, Cox S R, Schneider R P, Boucher J F & Clemence R G (2007) The pharmacokinetics of maropitant, a novel neurokinin type-1 receptor anatagonist, in dogs. J Vet Pharmacol Ther 30 (4), 336-344 PubMed.
• de la Puente-Redondo V A, Siedek E M, Benchaoui H A, Tilt N, Rowan T G & Clemence R G (2007) The anti-emetic efficacy of maropitant (Cerenia) in the treatment of ongoing emesis caused by a wide range of underlying clinical aetiologies in canine patients in Europe. JSAP 48 (2), 93-98 PubMed.
• de la Puetnte-Redondo V A, Tilt N, Rowan T G & Clemence R G (2007) Efficacy of maropitant for treatment and prevention of emesis caused by intravenous infusion of cisplatin in dogs. Am J Vet Res 68 (1), 48-56 PubMed.

• Pfizer Animal Health: http://www.pfizerah.com/cerenia/product%20information/overview.asp.

• Dr Clive Elwood MA VetMB MSc PhD CertSAC MRCVS DipACVIM DipECVIM-CA , RCVS Specialist in Small Animal Medicine, European Specialist in Veterinary Internal Medicine (Companion Animals), Davies Veterinary Specialists, Manor Farm Business Park, Higham Gobion, Hitchin, Hertfordshire SG5 3HR, UK.

Back to top
© Copyright Vetstream

CANIS GEN00862

---